RTTNews | Apr 19, 2021 04:26AM EDT

04:25 Monday, April 19, 2021 (RTTNews.com) - XBiotech (XBIT) said the FDA has granted permission to commence clinical trials with its drug candidate for treating patients with pancreatic cancer. The phase I/II study will evaluate the company's new drug candidate when added to the ONIVYDE/5-FU combination therapy.

XBiotech's new drug XB2001 is a naturally occurring antibody. It specifically targets a process potentially involved in the growth and spread of malignant tumors; and the drug also blocks inflammation associated with tissue injury, which may reduce toxicity associated with the chemotherapy.

Read the original article on RTTNews ( https://www.rttnews.com/3185843/xbiotech-fda-grants-permission-to-begin-trials-with-xb2001-therapy-in-pancreatic-cancer.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved